Emerging thrombotic effects of drug eluting stents

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 2, 2007, Pages 261-262

  Lang, Ninian N ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; MESSENGER RNA; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR; RAPAMYCIN; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

AUTOPSY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FIBRINOLYSIS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MICE, TRANSGENIC; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; RNA, MESSENGER; SIROLIMUS; STENTS; TISSUE PLASMINOGEN ACTIVATOR; UP-REGULATION;

EID: 33846412234     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000255308.41576.ae     Document Type: Editorial

References (12)

1. Shuchman M. Trading Restenosis for Thrombosis? New Questions about Drug-Eluting Stents. N Engl J Med. 2006;355:1949-1952.
2. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-959.
3. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
4. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-1193.
5. Urbich C, Dimmeler S. Endothelial progenitor cells functional characterization. Trends Cardiovasc Med. 2004;14:318-322.
6. Muldowney Iii JA, Stringham JR, Levy SE, Gleaves LA, Eren M, Piana RN, Vaughan DE. Antiproliferative Agents Alter Vascular Plasminogen Activator Inhibitor-1 Expression. A Potential Prothrombotic Mechanism of Drug-Eluting Stents. Arterioscler Thromb Vasc Biol. 2007;27:400-406.
7. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
8. Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation. 2002;106:491-496.
9. Thogersen AM, Jansson J-H, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women : Evidence for the Fibrinolytic System as an Independent Primary Risk Factor. Circulation. 1998;98:2241-2247.
10. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005;3:1879-1883.
11. Marcucci R, Brogi D, Sofi F, Giglioli C, Valente S, Liotta AA, Lenti M, Gori AM, Prisco D, Abbate R, Gensini GF. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart. 2006;92:377-381.
12. Camenzind ESP, Wijns W. A meta-analysis of first generation drug eluting stent programs. World Congress of Cardiology. Barcelona; September 2-5, 2006.